Mylan (NASDAQ:MYL) had its price objective hoisted by stock analysts at Morgan Stanley from $36.00 to $39.00 in a report released on Tuesday. The firm presently has a “hold” rating on the stock. Morgan Stanley’s price objective would suggest a potential upside of 7.14% from the stock’s previous close.
MYL has been the topic of a number of other research reports. Wells Fargo & Co reissued a “hold” rating on shares of Mylan in a research note on Thursday, August 2nd. ValuEngine upgraded Mylan from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. Royal Bank of Canada upgraded Mylan from a “sector perform” rating to an “outperform” rating and set a $53.00 target price on the stock in a report on Monday, August 13th. Mizuho cut Mylan from a “buy” rating to a “neutral” rating in a report on Friday, October 5th. Finally, Zacks Investment Research upgraded Mylan from a “strong sell” rating to a “hold” rating in a report on Tuesday, October 9th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. Mylan has a consensus rating of “Buy” and an average target price of $46.87.
Shares of MYL traded down $0.03 during midday trading on Tuesday, reaching $36.40. The stock had a trading volume of 1,125,268 shares, compared to its average volume of 5,571,985. Mylan has a 52 week low of $30.33 and a 52 week high of $47.82. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.77 and a current ratio of 1.29. The company has a market capitalization of $16.33 billion, a PE ratio of 7.98, a P/E/G ratio of 1.02 and a beta of 1.53.
Several hedge funds have recently modified their holdings of MYL. First Mercantile Trust Co. purchased a new position in Mylan in the second quarter valued at about $121,000. Stratos Wealth Partners LTD. purchased a new position in Mylan in the third quarter valued at about $183,000. CENTRAL TRUST Co grew its stake in Mylan by 1,057.8% in the second quarter. CENTRAL TRUST Co now owns 5,210 shares of the company’s stock valued at $188,000 after purchasing an additional 4,760 shares in the last quarter. Reilly Financial Advisors LLC grew its stake in Mylan by 69.4% in the third quarter. Reilly Financial Advisors LLC now owns 5,217 shares of the company’s stock valued at $191,000 after purchasing an additional 2,137 shares in the last quarter. Finally, FTB Advisors Inc. purchased a new position in Mylan in the second quarter valued at about $188,000. Institutional investors and hedge funds own 82.99% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.